Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

van Schie KA, Kruithof S, Ooijevaar-de Heer P, Derksen NIL, van de Bovenkamp FS, Saris A, Vidarsson G, Bentlage AEH, Jiskoot W, Romeijn S, Koning RI, Bos E, Stork EM, Koeleman CAM, Wuhrer M, Wolbink G, Rispens T.

Ann Rheum Dis. 2018 Jun 26. pii: annrheumdis-2018-213299. doi: 10.1136/annrheumdis-2018-213299. [Epub ahead of print]

PMID:
29945923
2.

Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot.

Bloem K, Schaap T, Boshuizen R, Kneepkens EL, Wolbink GJ, Vries A, Rispens T.

Bioanalysis. 2018 Jun 1;10(11):815-823. doi: 10.4155/bio-2018-0010. Epub 2018 Jun 4.

PMID:
29863412
3.

TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism.

Bloemendaal FM, Koelink PJ, van Schie KA, Rispens T, Peters CP, Buskens CJ, van der Bilt JD, Bemelman WA, Korf H, Sabino JG, Ponsioen CY, Te Velde AA, D'Haens GRAM, van den Brink GR, Wildenberg ME.

J Crohns Colitis. 2018 May 30. doi: 10.1093/ecco-jcc/jjy075. [Epub ahead of print]

PMID:
29860435
4.

Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability.

van de Bovenkamp FS, Derksen NIL, van Breemen MJ, de Taeye SW, Ooijevaar-de Heer P, Sanders RW, Rispens T.

Front Immunol. 2018 Apr 12;9:740. doi: 10.3389/fimmu.2018.00740. eCollection 2018.

5.

Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation.

Kustiawan I, Derksen NIL, Guhr T, Kruithof S, Jiskoot W, Vidarsson G, Rispens T.

PLoS One. 2018 Apr 10;13(4):e0195729. doi: 10.1371/journal.pone.0195729. eCollection 2018.

6.

Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases.

Dekkers G, Rispens T, Vidarsson G.

Front Immunol. 2018 Mar 19;9:553. doi: 10.3389/fimmu.2018.00553. eCollection 2018.

7.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

PMID:
29606564
8.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2018 Apr 1;57(4):771. doi: 10.1093/rheumatology/key056. No abstract available.

PMID:
29481646
9.

Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.

van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, van der Schoot CE, IJspeert H, van der Burg M, Gils A, Hafkenscheid L, Toes REM, Rombouts Y, Plomp R, Wuhrer M, van Ham SM, Vidarsson G, Rispens T.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1901-1906. doi: 10.1073/pnas.1711720115. Epub 2018 Feb 5.

PMID:
29432186
10.

Clinically relevant discrepancies between different rheumatoid factor assays.

Falkenburg WJJ, von Richthofen HJ, Koers J, Weykamp C, Schreurs MWJ, Bakker-Jonges LE, Haagen IA, Lems WF, Hamann D, van Schaardenburg D, Rispens T.

Clin Chem Lab Med. 2018 Feb 10. pii: /j/cclm.ahead-of-print/cclm-2017-0988/cclm-2017-0988.xml. doi: 10.1515/cclm-2017-0988. [Epub ahead of print]

PMID:
29427550
11.

Repeated vaccination with tetanus toxoid of plasma donors with pre-existing specific IgE transiently elevates tetanus-specific IgE but does not induce allergic symptoms.

Unger PP, Makuch M, Aalbers M, Derksen NIL, Ten Brinke A, Aalberse RC, Rispens T, van Ham SM.

Clin Exp Allergy. 2018 Apr;48(4):479-482. doi: 10.1111/cea.13107. Epub 2018 Mar 7. No abstract available.

PMID:
29383792
12.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

13.

Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice.

Dekkers G, Bentlage AEH, Plomp R, Visser R, Koeleman CAM, Beentjes A, Mok JY, van Esch WJE, Wuhrer M, Rispens T, Vidarsson G.

Mol Immunol. 2018 Feb;94:54-60. doi: 10.1016/j.molimm.2017.12.006. Epub 2017 Dec 19.

14.

Pitfalls in the detection of citrullination and carbamylation.

Verheul MK, van Veelen PA, van Delft MAM, de Ru A, Janssen GMC, Rispens T, Toes REM, Trouw LA.

Autoimmun Rev. 2018 Feb;17(2):136-141. doi: 10.1016/j.autrev.2017.11.017. Epub 2017 Dec 2. Review.

15.

Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies.

Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu ML.

J Biol Chem. 2018 Jan 12;293(2):651-661. doi: 10.1074/jbc.RA117.000303. Epub 2017 Nov 17.

16.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2017 Nov 13. pii: annrheumdis-2017-212602. doi: 10.1136/annrheumdis-2017-212602. [Epub ahead of print] No abstract available.

PMID:
29133475
17.

Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human Plasma.

van Beek AE, Pouw RB, Brouwer MC, van Mierlo G, Geissler J, Ooijevaar-de Heer P, de Boer M, van Leeuwen K, Rispens T, Wouters D, Kuijpers TW.

Front Immunol. 2017 Oct 18;8:1328. doi: 10.3389/fimmu.2017.01328. eCollection 2017.

18.

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

van Kempen ZL, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):822-823. doi: 10.1177/1352458517734073. Epub 2017 Oct 9. No abstract available.

19.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2017 Nov 1;56(11):2025-2030. doi: 10.1093/rheumatology/kex284. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):771.

PMID:
28977504
20.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
21.

B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation.

Vergroesen RD, Slot LM, Hafkenscheid L, Koning MT, van der Voort EIH, Grooff CA, Zervakis G, Veelken H, Huizinga TWJ, Rispens T, Scherer HU, Toes REM.

Ann Rheum Dis. 2018 Jun;77(6):956-958. doi: 10.1136/annrheumdis-2017-212052. Epub 2017 Aug 23. No abstract available.

PMID:
28835463
22.

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.

Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G.

Front Immunol. 2017 Aug 2;8:877. doi: 10.3389/fimmu.2017.00877. eCollection 2017.

23.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381. [Epub ahead of print]

PMID:
28823223
24.

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Kneepkens EL, Pouw MF, Wolbink GJ, Schaap T, Nurmohamed MT, de Vries A, Rispens T, Bloem K.

Br J Clin Pharmacol. 2017 Nov;83(11):2474-2484. doi: 10.1111/bcp.13371. Epub 2017 Aug 22.

PMID:
28791718
25.

The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM.

Kempers AC, Hafkenscheid L, Dorjée AL, Moutousidou E, van de Bovenkamp FS, Rispens T, Trouw LA, van Oosterhout M, Huizinga TW, Toes R, Scherer HU.

Ann Rheum Dis. 2018 Jul;77(7):1087-1088. doi: 10.1136/annrheumdis-2017-211533. Epub 2017 Jul 26. No abstract available.

PMID:
28747327
26.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
27.

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.

Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, Vidarsson G, Kuijpers TW.

J Immunol. 2017 Jul 1;199(1):204-211. doi: 10.4049/jimmunol.1700116. Epub 2017 May 31.

28.

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.

29.

Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.

Bloem K, Hernández-Breijo B, Martínez-Feito A, Rispens T.

Ther Drug Monit. 2017 Aug;39(4):327-332. doi: 10.1097/FTD.0000000000000404. Review.

PMID:
28463887
30.

Affinity of human IgG subclasses to mouse Fc gamma receptors.

Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G.

MAbs. 2017 Jul;9(5):767-773. doi: 10.1080/19420862.2017.1323159. Epub 2017 May 2.

31.

Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.

van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2017 Jul;76(7):1285-1288. doi: 10.1136/annrheumdis-2016-211035. Epub 2017 Apr 28.

PMID:
28455438
32.

Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.

Caldano M, Raoul W, Rispens T, Bertolotto A.

Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393. Review.

33.

Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Trouw LA, Rispens T, Toes REM.

Nat Rev Rheumatol. 2017 Jun;13(6):331-339. doi: 10.1038/nrrheum.2017.15. Epub 2017 Mar 9. Review.

PMID:
28275265
34.

Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease.

Culver EL, Sadler R, Bateman AC, Makuch M, Cargill T, Ferry B, Aalberse R, Barnes E, Rispens T.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1444-1452.e6. doi: 10.1016/j.cgh.2017.02.007. Epub 2017 Feb 20.

35.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
36.

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.

Harrer A, Pilz G, Oppermann K, Sageder M, Afazel S, Haschke-Becher E, Rispens T, de Vries A, McCoy M, Stevanovic V, Hitzl W, Trinka E, Kraus J, Sellner J, Wipfler P.

Clin Immunol. 2017 Mar;176:87-93. doi: 10.1016/j.clim.2017.01.001. Epub 2017 Jan 17.

PMID:
28108364
37.

Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study.

Aeschlimann FA, Angst F, Hofer KD, Cannizzaro Schneider E, Schroeder-Kohler S, Lauener R, van der Kleij D, Rispens T, Saurenmann RK.

J Rheumatol. 2017 Mar;44(3):334-341. doi: 10.3899/jrheum.160072. Epub 2017 Jan 15.

PMID:
28089968
38.

Room temperature structure of human IgG4-Fc from crystals analysed in situ.

Davies AM, Rispens T, Ooijevaar-de Heer P, Aalberse RC, Sutton BJ.

Mol Immunol. 2017 Jan;81:85-91. doi: 10.1016/j.molimm.2016.11.021. Epub 2016 Dec 1.

39.

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.

Dekkers G, Plomp R, Koeleman CA, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G.

Sci Rep. 2016 Nov 22;6:36964. doi: 10.1038/srep36964.

40.

Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.

Hartholt RB, Wroblewska A, Herczenik E, Peyron I, Ten Brinke A, Rispens T, Nolte MA, Slot E, Claassens JW, Nimmerjahn F, Verbeek JS, Voorberg J.

J Thromb Haemost. 2017 Feb;15(2):329-340. doi: 10.1111/jth.13570. Epub 2017 Jan 19.

PMID:
27868337
41.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

42.

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T.

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. No abstract available.

PMID:
27717666
43.

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange.

van Schie KA, Ooijevaar-de Heer P, Dijk L, Kruithof S, Wolbink G, Rispens T.

Sci Rep. 2016 Sep 8;6:32747. doi: 10.1038/srep32747.

44.

Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.

Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G.

AAPS J. 2017 Jan;19(1):161-171. doi: 10.1208/s12248-016-9981-3. Epub 2016 Sep 6.

PMID:
27600137
45.

The Immunobiology of Immunoglobulin G4.

Lighaam LC, Rispens T.

Semin Liver Dis. 2016 Aug;36(3):200-15. doi: 10.1055/s-0036-1584322. Epub 2016 Jul 28. Review.

PMID:
27466791
46.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.

PMID:
27440258
47.

Inactivated pepsin inhibits neutrophil activation by Fcgamma-receptor-dependent and independent stimuli.

Kustiawan I, Derksen N, Rispens T.

Clin Immunol. 2016 Aug;169:85-88. doi: 10.1016/j.clim.2016.06.008. Epub 2016 Jun 29.

PMID:
27368805
48.

The Developmental History of IgE and IgG4 Antibodies in Relation to Atopy, Eosinophilic Esophagitis, and the Modified TH2 Response.

Aalberse RC, Platts-Mills TA, Rispens T.

Curr Allergy Asthma Rep. 2016 Jun;16(6):45. doi: 10.1007/s11882-016-0621-x. Review.

49.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767
50.

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.

Eur J Neurol. 2016 Jun;23(6):1079-85. doi: 10.1111/ene.12988. Epub 2016 Mar 27.

PMID:
27018481

Supplemental Content

Loading ...
Support Center